Who are Arm A: FOLFIRI or FOLFOX + Bevacizumab's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/arm-a-folfiri-or-folfox-bevacizumab.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Arm A: FOLFIRI or FOLFOX + Bevacizumab — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Arm A: FOLFIRI or FOLFOX + Bevacizumab (Arm A: FOLFIRI or FOLFOX + Bevacizumab) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Chemotherapy combination + VEGF inhibitor. Area: Oncology.

phase 3 Chemotherapy combination + VEGF inhibitor DNA (chemotherapy); VEGF (bevacizumab) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Arm A: FOLFIRI or FOLFOX + Bevacizumab (Arm A: FOLFIRI or FOLFOX + Bevacizumab) — Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS. FOLFIRI or FOLFOX chemotherapy regimens combined with bevacizumab inhibit tumor cell division and angiogenesis to treat colorectal cancer.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Arm A: FOLFIRI or FOLFOX + Bevacizumab TARGET	Arm A: FOLFIRI or FOLFOX + Bevacizumab	Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS	phase 3	Chemotherapy combination + VEGF inhibitor	DNA (chemotherapy); VEGF (bevacizumab)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Chemotherapy combination + VEGF inhibitor class)

Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Arm A: FOLFIRI or FOLFOX + Bevacizumab — Competitive Intelligence Brief. https://druglandscape.com/ci/arm-a-folfiri-or-folfox-bevacizumab. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab